Mutations of the androgen receptor gene identified in perineal hypospadias

J A Batch, B A J Evans, I A Hughes, M N Patterson

Abstract
Hypospadias is a common urological abnormality and may occur in simple (glandular or penile) or severe forms (perineal). Perineal hypospadias often occurs in association with other genital abnormalities, such as bilateral cryptorchidism and micropenis, and may also be the result of partial androgen insensitivity. We have investigated the androgen binding status and androgen receptor gene of boys from two unrelated families. The first pair of brothers had partial androgen insensitivity with perineal hypospadias, bilateral cryptorchidism, and micropenis, while the other boys had isolated perineal hypospadias. Qualitative androgen binding defects were shown in both sets of brothers and different point mutations of the androgen receptor gene were found in the two families. These findings suggest that the genital abnormalities in the affected brothers result from defects in the androgen receptor. Furthermore, severe familial hypospadias may be a previously unrecognised part of the phenotypic spectrum of the partial androgen insensitivity syndrome. This study provides valuable information for the genetic counselling of families affected by this X linked genital abnormality.

(J Med Genet 1993;30:198–201)

Hypospadias is a disorder of male external genital development in which the urethral orifice is found on the ventral surface of the penis rather than at the tip of the glans. It is a relatively common congenital abnormality with an incidence of 0.2 to 0.6%.1 It may be classified as simple (glandular or penile) or severe (perineal) on the basis of the anatomical location of the urethral meatus. In three-quarters of cases the hypospadias is glandular or penile in location and occurs in isolation.2 Perineal hypospadias is less common and usually occurs in association with severe genital abnormalities such as micropenis, bifid scrotum, and cryptorchidism. The aetiology of hypospadias is poorly understood although varying modes of inheritance have been deduced from family studies, and significant associations with environmental factors have also been noted.2

Male sexual differentiation is androgen dependent. It is therefore possible that hypospadias may result from abnormal androgen synthesis or action. Endocrine studies in hypospadias have, however, not yielded consistent results. We and others have shown normal gonadotrophin production with appropriate testosterone synthesis and metabolism in simple glandular or penile hypospadias.3,4 Conversely, perineal hypospadias has been reported to be caused by uncommon defects in testosterone biosynthesis, such as 17-ketosteroid reductase deficiency, 5α-reductase deficiency, and 3β-hydroxysteroid dehydrogenase deficiency.5

The partial androgen insensitivity syndrome (PAIS) comprises a spectrum of disorders with a phenotype ranging from perineal hypospadias with cryptorchidism and micropenis (mild androgenisation) to clinical hypogonadism and labial fusion (severe androgenisation).6 Subjects with PAIS all have a normal 46,XY karyotype, normal testosterone synthesis and metabolism, but have a defect in target cell androgen action which may be the result of a defective androgen receptor. It has been estimated that 10 to 50% of boys with PAIS have androgen binding abnormalities, suggesting that they have an abnormality of the androgen receptor.7,8 A complete form (CAIS) also exists and is associated with female external genitalia and usually absent androgen binding.6

The androgen receptor (AR) gene is located on the X chromosome and comprises eight exons.9,10 Like other members of the steroid receptor superfamily, the androgen receptor protein is divided into three distinct functional domains: a C-terminal androgen binding domain encoded by exons D to H, a central DNA binding domain (exons B and C), and an N-terminal domain (exon A) which has a less well defined role in transcriptional regulation.11,12 Mutations have recently been identified in the androgen receptor gene in subjects with both complete and partial androgen insensitivity.4,13 As part of a larger study of patients with abnormal male sexual differentiation spanning a wide phenotypic range,14 we have studied four boys from two unrelated families to assess their androgen binding status and to determine whether androgen receptor gene abnormalities may be responsible for the genital abnormalities. Boys from the first family had perineal hypospadias, bilateral cryptorchidism, and micropenis and fulfilled the diagnostic criteria of the partial androgen insensitivity syndrome. In contrast, brothers from the second family had only isolated perineal hypospadias, a condition not usually considered to be part of the PAIS phenotypic spectrum.

Patients

FAMILY 1

The two brothers in this Kuwaiti family (subjects 1A and 1B) were born to non-consanguineous parents and presented in the neonatal...
Results of androgen binding assay in the four boys. Normal values for the assay are given as mean (SD).

<table>
<thead>
<tr>
<th>Subject</th>
<th>$B_{max}$ (nM/lugDNA)</th>
<th>$K_d$ (nM/l)</th>
<th>Thermolability (% reduction at 40°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1A</td>
<td>587</td>
<td>3-5</td>
<td>30</td>
</tr>
<tr>
<td>1B</td>
<td>628</td>
<td>4-3</td>
<td>31</td>
</tr>
<tr>
<td>2A</td>
<td>977</td>
<td>3-1</td>
<td>57</td>
</tr>
<tr>
<td>2B</td>
<td>2097</td>
<td>3-1</td>
<td>54</td>
</tr>
<tr>
<td>Normal</td>
<td>814 (168)</td>
<td>0-91 (0-26)</td>
<td>6 (5)</td>
</tr>
</tbody>
</table>

ANDROGEN BINDING ASSAY

Androgen binding was measured in genital skin fibroblasts using a whole cell binding assay. Parameters derived from this assay included the receptor concentration ($B_{max}$), binding affinity ($K_d$), and the stability of androgen binding at 40°C (thermolability).

PCR-SSCP ANALYSIS OF THE ANDROGEN RECEPTOR GENE

The androgen receptor gene was screened for mutations using a rapid and sensitive technique, PCR-single strand conformation polymorphism (SSCP) described elsewhere. Genomic DNA was prepared from genital skin fibroblasts by standard methods. Fourteen pairs of oligonucleotide primers were used to amplify the coding regions of the androgen receptor gene to yield segments less than 350 bases.

DNA SEQUENCING OF PCR PRODUCTS

Preparative PCR reactions were carried out in a total volume of 25 μl, as a scaled up version of the basic PCR reaction described. The PCR reaction was then loaded on to an agarose gel and the DNA extracted using the QIAEX® agarose gel extraction kit. A 50 μl asymmetrical PCR reaction was performed using 5 ng DNA, a 20:1 ratio of primers (that is, 20 pmol:1 pmol), 50 μmol/l dNTPs, 5 μl Parr buffer (Cambio Ltd), and 1 unit of DNA Taq polymerase (Cambio Ltd). The PCR product was purified by phenol and chloroform extractions and isopropanol precipitation. Subsequently the products were sequenced with the limiting primer using a Sequenase® kit.

FAMILY 2

The two brothers in this family (subjects 2A and 2B) were also born to unrelated parents. Both presented at birth with perineal hypospadias but no associated genital or general physical abnormality. Male sex of rearing was assigned at birth. There was no family history of a similar disorder. Both brothers had a normal 46,XY karyotype. Results of endocrine investigations in the brothers showed normal testosterone biosynthesis and metabolism. As part of their investigation, genital skin fibroblasts grown from biopsies taken at the time of corrective hypospadias surgery were assayed for androgen binding (see Results). Intravenous pyelograms (IVP) and micturating cystourethrogram (MCUG) showed that neither boy had any upper renal tract abnormality. At puberty both boys had some spontaneous testicular enlargement, but little pubic hair development or penile enlargement. Neither boy responded to therapeutic trials of intramuscular testosterone given to augment pubertal virilisation. Both boys are now lost to follow up, so their functional status as adult males is unknown.

METHODS

TISSUE CULTURE

Fibroblast cell lines were established from genital skin biopsies obtained at surgery, by primary explantation in E199 medium containing 20% fetal calf serum and supplemented with penicillin, streptomycin, and glutamine as previously described. The serum was reduced to 10% after the second passage and maintained at that level thereafter. Cells were grown at 37°C in 5% CO₂.

Figure 1 SSCP analysis of the androgen receptor gene. (A) Band shift in amplified exon G fragments from subjects 1A and 1B. (B) Band shift in exon H in subjects 2A and 2B. The normal pattern for male and female controls is also shown for both exons. Both gels were run at 4°C without glycerol.
PCR–SSCP ANALYSIS
The presence of mutations is indicated by a shift in the mobility of denatured PCR segments when run on a non-denaturing gel. In subjects 1A and 1B, an abnormal DNA band shift compared to control DNA was found in exon G (fig 1A). This abnormality was detected readily under both sets of electrophoresis conditions outlined above. This was the only band shift detected in these boys. In subjects 2A and 2B, an abnormal DNA band shift compared to control DNA was found in exon H. Again the SSCP band shift was detected under both sets of conditions, but was more easily seen when the gel was run at 4°C without glycerol (fig 1B). No other abnormalities were detected in any other part of the gene examined. The band shift detected in subjects 2A and 2B was more subtle than that detected in subjects 1A and 1B. SSCP analysis therefore suggested that subjects 1A and 1B carried an exon G mutation, and subjects 2A and 2B an exon H mutation in the AR gene.

DNA SEQUENCING OF PCR PRODUCTS
The polyglutamine repeat region of exon A consisted of 24 residues in subjects 1A and 1B, and 27 residues in subjects 2A and 2B and was within the range defined for normal populations. No mutation was found in this region in the four boys. Direct sequencing of exon G in subjects 1A and 1B confirmed the presence of a point mutation (guanine to adenine), causing an amino acid change from arginine to histidine at position 855 (fig 2). Sequencing of exon H in subjects 2A and 2B showed a point mutation (thymine to guanine), causing an amino acid change from isoleucine to methionine at position 869 (fig 3). In the four boys, mutations were sequenced on both strands. The mutations are diagrammatically summarised in fig 4.

Results
ANDROGEN BINDING ASSAY
The results of androgen binding assays for the four boys are shown in the table. Both pairs of brothers showed a clear qualitative defect in androgen binding indicated by the high \( K_d \) (that is, low androgen binding affinity) and thermodamability of binding. Receptor concentration was not diminished in any subject. The significance of the high \( B_{max} \) in subject 2B is uncertain. These abnormal binding data suggested that the androgen receptor was defective.

Discussion
This study shows that familial perineal hypospadias occurring alone or in association with cryptorchidism and micropenis may be associated with abnormal androgen binding and point mutations of the androgen receptor gene. The findings also suggest that abnormalities in androgen binding resulting from the AR gene mutations may be the cause of the abnormal genital development. Thus this study expands the phenotypic spectrum of PAIS to include

Figure 2  Sequencing of point mutations in exon G in subjects 1A and 1B. Portions of a sequencing gel are shown with a normal control on the left and the mutant on the right. The altered nucleotide is indicated by an asterisk, and the resultant amino acid change is also shown. The numbering used corresponds to Lubahn et al.21

Figure 3  Sequencing of point mutations in exon II in subjects 2A and 2B. The layout and labelling of this figure are the same as in fig 2.

Figure 4  Androgen receptor gene mutations. The position of the mutations and the resulting amino acid changes are shown, in relation to the major functional domains of the AR. The boxes labelled A to H indicate the extents of the receptor encoded by each of the exons.22
Mutations of the androgen receptor gene identified in perineal hypospadias.

familial perineal hypospadias. Inclusion of familial perineal hypospadias in the spectrum of PAIS allows appropriate genetic counselling of families affected by this X linked condition.

The mutations identified in the two families are within the androgen binding domain of the androgen receptor gene, consistent with the demonstrated qualitative androgen binding abnormalities. The same mutation at amino acid 855 (arginine to histidine) has previously been reported in a patient with PAIS23 who had similar qualitative androgen binding abnormalities to our patients (subjects 1A and 1B). In addition, an arginine to cysteine change at position 855 has also been identified in a CAIS patient with no detectable androgen binding.24 This less conservative amino acid change is consistent with the more severe binding defect and clinical phenotype. The mutation we have delineated at amino acid 869 in subjects 2A and 2B is unique. Other recent studies of PAIS have also shown AR gene mutations.13,14 No study to date has documented AR gene mutations in isolated severe hypospadias, nor provided evidence that isolated severe hypospadias forms part of the partial androgen insensitivity syndrome. It is noteworthy that the subjects in our two families had virtually indistinguishable qualitative androgen binding abnormalities, yet showed a marked difference in the severity of the genital abnormality. A possible explanation is that the two AR gene mutations have different effects on target gene activation and full expression of androgenic effect. Expression studies of the mutant receptors could be designed to test this hypothesis and confirm that the mutations are responsible for the binding defect.

While these studies suggest that AR gene mutations are a cause of perineal hypospadias, it is unlikely that simple hypospadias is associated with AR gene abnormalities. However, in families in whom testosterone biosynthetic defects have been excluded as a cause of perineal hypospadias, we recommend that androgen binding studies be performed. If androgen binding abnormalities are found, then screening the AR gene may show a mutation responsible for the abnormal androgen binding and genital phenotype. The information gained may form the basis for appropriate genetic counselling in such families.

This work was supported by the Medical Research Council and the Wellcome Trust. JB was supported by grants from the Smith and Nephew Foundation, the University of Melbourne, Australia (The Henry and Rachael Ackman Travelling Scholarship in Medicine), the Royal Australasian College of Physicians (CRB Blackburn Scholarship), and the Royal Children’s Hospital, Melbourne (Uncle Bob’s Scholarship). Mr Scott and Mr Lari, paediatric surgeons, are gratefully acknowledged for obtaining samples at surgery for analysis.